Synthesis and In Silico Studies of Quinazolinones as PARP-1 Inhibitors


Cite item

Full Text

Abstract

Background:Cancer is a leading threat to humankind, accounting for nearly one million deaths in 2018, and the expected number of cancer-related deaths in 2040 is more than 16 million. The most common causes of cancer deaths are lung, colorectal, stomach, liver and breast cancer, while the highest number of new cancer cases belong to lung, breast, colorectal, prostate, stomach and liver cancer.

Introduction:PARP-1 is an enzyme that plays an important role in DNA repair, cell propagation/survival and death due to its influence on numerous biological processes. Quinazolinones represent an important scaffold in medicinal chemistry and have a broad spectrum of biological activities.

Methods:In this study, we have synthesized quinazolinones by reaction of 2-aminobenzamide and substituted aldehydes. Molecular docking studies of synthesized compounds were performed for their PARP-1 binding affinities using Schrodinger 2016 software. In silico ADME studies were also performed for the synthesized compounds using the QikProp tool of Schrodinger software.

Results:Results of molecular docking studies indicated that synthesized quinazolinones had a good affinity towards active site of PARP-1 and compound 4 had the best docking score (-10.343). Results of ADME studies indicated the drug-like properties of synthesized compounds, which make them suitable drug candidates.

Conclusion:All the synthesized compounds have a better docking score than niraparib (-9.05). Further, the synthesized compounds have a favorable ADME profile. Therefore, they may serve as important leads in discovering PARP-1 inhibitors.

About the authors

Maneesh Guleria

Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Adarsh Kumar

Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Ankit Singh

Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Pradeep Kumar

Pharmaceutical Sciences and Natural Products, Central University of Punjab

Author for correspondence.
Email: info@benthamscience.net

References

  1. Kumar, A.; Bhagat, K.K.; Singh, A.K.; Singh, H.; Angre, T.; Verma, A.; Khalilullah, H.; Jaremko, M.; Emwas, A.H.; Kumar, P. Medicinal chemistry perspective of pyrido2,3- dpyrimidines as anticancer agents. RSC Advances, 2023, 13(10), 6872-6908. doi: 10.1039/D3RA00056G PMID: 36865574
  2. Kumar, A.; Singh, A.K.; Singh, H.; Vijayan, V.; Kumar, D.; Naik, J.; Thareja, S.; Yadav, J.P.; Pathak, P.; Grishina, M.; Verma, A.; Khalilullah, H.; Jaremko, M.; Emwas, A.H.; Kumar, P. Nitrogen containing heterocycles as anticancer agents: A medicinal chemistry perspective. Pharmaceuticals, 2023, 16(2), 299-368. doi: 10.3390/ph16020299 PMID: 37259442
  3. Angre, T; Kumar, A; Singh, AK; Thareja, S; Kumar, P Role of collagen regulators in cancer treatment: A comprehensive review. Anti-Cancer Agents Med. Chem., 2022, 22(17), 2956-2984.
  4. Jagtap, P.; Szabó, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov., 2005, 4(5), 421-440. doi: 10.1038/nrd1718 PMID: 15864271
  5. Wang, L.; Liang, C.; Li, F.; Guan, D.; Wu, X.; Fu, X.; Lu, A.; Zhang, G. PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs. Int. J. Mol. Sci., 2017, 18(10), 2111. doi: 10.3390/ijms18102111
  6. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer, 2010, 10(4), 293-301. doi: 10.1038/nrc2812 PMID: 20200537
  7. Langelier, M.F.; Planck, J.L.; Roy, S.; Pascal, J.M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science, 2012, 336(6082), 728-732. doi: 10.1126/science.1216338 PMID: 22582261
  8. Ali, A.A.E.; Timinszky, G.; Arribas-Bosacoma, R.; Kozlowski, M.; Hassa, P.O.; Hassler, M.; Ladurner, A.G.; Pearl, L.H.; Oliver, A.W. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat. Struct. Mol. Biol., 2012, 19(7), 685-692. doi: 10.1038/nsmb.2335 PMID: 22683995
  9. Loeffler, P.A.; Cuneo, M.J.; Mueller, G.A.; DeRose, E.F.; Gabel, S.A.; London, R.E. Structural studies of the PARP-1 BRCT domain. BMC Struct. Biol., 2011, 11(1), 37. doi: 10.1186/1472-6807-11-37 PMID: 21967661
  10. Gibson, B.A.; Kraus, W.L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol., 2012, 13(7), 411-424. doi: 10.1038/nrm3376 PMID: 22713970
  11. Schiewer, M.J.; Knudsen, K.E. Transcriptional roles of PARP1 in cancer. Mol. Cancer Res., 2014, 12(8), 1069-1080. doi: 10.1158/1541-7786.MCR-13-0672 PMID: 24916104
  12. Schiewer, M.J.; Mandigo, A.C.; Gordon, N.; McNair, C.; Lallas, C.D.; Trabulsi, E.J.; Leiby, B.; Knudsen, K.E. PARP-1 regulation of DNA repair factor availability. J. Clin. Oncol., 2019, 37(7_suppl), 269-269. doi: 10.1200/JCO.2019.37.7_suppl.269
  13. Jiang, X.; Li, W.; Li, X.; Bai, H.; Zhang, Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag. Res., 2019, 11, 4371-4390. doi: 10.2147/CMAR.S200524 PMID: 31191001
  14. Abu-Hashem, A.A.; Abu-Zied, K.M.; AbdelSalam Zaki, M.E.; El-Shehry, M.F.; Awad, H.M.; Khedr, M.A. Design, synthesis, and anticancer potential of the enzyme (parp-1) inhibitor with computational studies of new triazole, thiazolidinone, - thieno 2, 3-d pyrimidinones. Lett. Drug Des. Discov., 2020, 17(6), 799-817. doi: 10.2174/1570180817666200117114716
  15. Verma, S.; Pathania, A.S.; Baranwal, S.; Kumar, P. Synthesis and in silico studies of quinazolinone derivatives as PARP-1 inhibitors. Lett. Drug Des. Discov., 2020, 17(12), 1552-1565. doi: 10.2174/1570180817999200719152959
  16. Chawla, A.; Batra, C. Recent advances of quinazolinone derivatives as marker for various biological activities. Inter. Res. J. Pharm., 2013, 4(3), 49-58. doi: 10.7897/2230-8407.04309
  17. Abdel Gawad, N.M.; Georgey, H.H.; Youssef, R.M.; El-Sayed, N.A. Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)-ones and 4, 6- disubstituted- 1, 2, 3, 4-tetrahydroquinazolin-2H-ones. Eur. J. Med. Chem., 2010, 45(12), 6058-6067. doi: 10.1016/j.ejmech.2010.10.008 PMID: 21051122
  18. Rana, A.M.; Desai, K.R.; Jauhari, S. Synthesis, characterization, and pharmacological evaluation of 1-2-(6-nitro-4-oxo-2-phenyl-4H-quinazolin-3-yl)-ethyl-3-phenyl ureas. Med. Chem. Res., 2013, 22(1), 225-233. doi: 10.1007/s00044-012-0004-3
  19. Kumar, A.; Sharma, S.; Archana; Bajaj, K.; Sharma, S.; Panwar, H.; Singh, T.; Srivastava, V.K. Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors. Bioorg. Med. Chem., 2003, 11(23), 5293-5299. doi: 10.1016/S0968-0896(03)00501-7 PMID: 14604693
  20. Kavitha, K.; Srinivasan, N.; Haribabu, Y. A review on quinazolinone and its derivatives with diverse biological activities. World J. Pharm. Pharm. Sci., 2018, 7(4), 628-649.
  21. Wang, Z.; Wang, M.; Yao, X.; Li, Y.; Tan, J.; Wang, L.; Qiao, W.; Geng, Y.; Liu, Y.; Wang, Q. Design, synthesis and antiviral activity of novel quinazolinones. Eur. J. Med. Chem., 2012, 53, 275-282. doi: 10.1016/j.ejmech.2012.04.010 PMID: 22546200
  22. Hemalatha, K.; Girija, K. Synthesis of some novel 2, 3-disubstituted quinazolinone derivatives as analgesic and anti-inflammatory agents. Int. J. Pharm. Pharm. Sci., 2011, 3(2), 103-106.
  23. Rajput, R.; Mishra, A.P. A review on biological activity of quinazolinones. Int. J. Pharma Sci., 2012, 4(2), 66-70.
  24. Zhu, S.; Wang, J.; Chandrashekar, G.; Smith, E.; Liu, X.; Zhang, Y. Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents. Eur. J. Med. Chem., 2010, 45(9), 3864-3869. doi: 10.1016/j.ejmech.2010.05.040 PMID: 20538379
  25. Darwish, K.; Dakhil, O. A Review on synthesis and biological profiles of some quinazolines and (4H)-3, 1-quinazolin-4-ones of active substituents and their uses as starting materials in reaction schemes. Libyan J. Sci. Tech., 2017, 6(1), 8-13.
  26. Wang, Y.Q.; Wang, P.Y.; Wang, Y.T.; Yang, G.F.; Zhang, A.; Miao, Z.H. An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy. J. Med. Chem., 2016, 59(21), 9575-9598. doi: 10.1021/acs.jmedchem.6b00055 PMID: 27416328
  27. Giannini, G.; Battistuzzi, G.; Vesci, L.; Milazzo, F.M.; De Paolis, F.; Barbarino, M.; Guglielmi, M.B.; Carollo, V.; Gallo, G.; Artali, R.; Dallavalle, S. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold. Bioorg. Med. Chem. Lett., 2014, 24(2), 462-466. doi: 10.1016/j.bmcl.2013.12.048 PMID: 24388690
  28. Iwashita, A.; Hattori, K.; Yamamoto, H.; Ishida, J.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; Kinoshita, T.; Warizaya, M.; Ohkubo, M.; Matsuoka, N.; Mutoh, S. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett., 2005, 579(6), 1389-1393. doi: 10.1016/j.febslet.2005.01.036 PMID: 15733846
  29. Orvieto, F.; Branca, D.; Giomini, C.; Jones, P.; Koch, U.; Ontoria, J.M.; Palumbi, M.C.; Rowley, M.; Toniatti, C.; Muraglia, E. Identification of substituted pyrazolo1,5-aquinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4196-4200. doi: 10.1016/j.bmcl.2009.05.113 PMID: 19541484
  30. Hattori, K.; Kido, Y.; Yamamoto, H.; Ishida, J.; Iwashita, A.; Mihara, K. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett., 2007, 17(20), 5577-5581. doi: 10.1016/j.bmcl.2007.07.091 PMID: 17804225
  31. Kulkarni, S.S.; Singh, S.; Shah, J.R.; Low, W.K.; Talele, T.T. Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors. Eur. J. Med. Chem., 2012, 50, 264-273. doi: 10.1016/j.ejmech.2012.02.001 PMID: 22365563
  32. Kim, N.Y.; Cheon, C.H. Synthesis of quinazolinones from anthranilamides and aldehydes via metal-free aerobic oxidation in DMSO. Tetrahedron Lett., 2014, 55(15), 2340-2344. doi: 10.1016/j.tetlet.2014.02.065
  33. Van Den Driessche, G.; Fourches, D. Adverse drug reactions triggered by the common HLA-B*57:01 variant: A molecular docking study. J. Cheminform., 2017, 9(1), 13. doi: 10.1186/s13321-017-0202-6 PMID: 28303164
  34. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des., 2013, 27(3), 221-234. doi: 10.1007/s10822-013-9644-8 PMID: 23579614
  35. Kumar, S.; Singh, J.; Narasimhan, B.; Shah, S.A.A.; Lim, S.M.; Ramasamy, K.; Mani, V. Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Chem. Cent. J., 2018, 12(1), 106. doi: 10.1186/s13065-018-0475-5 PMID: 30345469
  36. Sharma, V.; Sharma, P.C.; Kumar, V. In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Adv. Chem., 2016, 2016(7), 1-9. doi: 10.1155/2016/5409387
  37. Deep, A.; Singh, J.; Kumar, M.; Mansuri, R.; Sahoo, G.C. Inhibitor designing, virtual screening, and docking studies for methyltransferase: A potential target against dengue virus. J. Pharm. Bioallied Sci., 2016, 8(3), 188-194. doi: 10.4103/0975-7406.171682 PMID: 27413346
  38. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177-6196. doi: 10.1021/jm051256o PMID: 17034125
  39. Lenselink, E.B.; Louvel, J.; Forti, A.F.; van Veldhoven, J.P.D.; de Vries, H.; Mulder-Krieger, T.; McRobb, F.M.; Negri, A.; Goose, J.; Abel, R.; van Vlijmen, H.W.T.; Wang, L.; Harder, E.; Sherman, W.; IJzerman, A.P.; Beuming, T. Predicting binding affinities for GPCR ligands using free-energy perturbation. ACS Omega, 2016, 1(2), 293-304. doi: 10.1021/acsomega.6b00086 PMID: 30023478
  40. Kalra, S.; Joshi, G.; Munshi, A.; Kumar, R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur. J. Med. Chem., 2017, 142, 424-458. doi: 10.1016/j.ejmech.2017.08.071 PMID: 28911822
  41. Graziani, G.; Szabó, C. Clinical perspectives of PARP inhibitors. Pharmacol. Res., 2005, 52(1), 109-118. doi: 10.1016/j.phrs.2005.02.013 PMID: 15911339
  42. Ghose, A.K.; Viswanadhan, V.N.; Wendoloski, J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem., 1999, 1(1), 55-68. doi: 10.1021/cc9800071 PMID: 10746014
  43. Shahbazi, S.; Sahrawat, T.R.; Ray, M.; Dash, S.; Kar, D.; Singh, S. Drug targets for cardiovascular-safe anti-inflammatory: In silico rational drug studies. PLoS One, 2016, 11(6), e0156156. doi: 10.1371/journal.pone.0156156 PMID: 27258084
  44. Vattathara, J.J.; Prakash, O.; Subhramanian, S.; Satheeshkumar, M.K.; Xavier, T.; Anil, M.; Pillai, G.S.; Anandakuttan, A.; Radhakrishnan, S.; Sivanarayanan, T.B.; Akk, U.; Mohan, C.G.; Menon, K.N. Substrate specifc inhibitor designed against the immunomodulator GMF-beta reversed the experimental autoimmune encephalomyelitis. Sci. Rep., 2020, 10(1), 3790. doi: 10.1038/s41598-020-60710-2 PMID: 32123210

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers